What is Humacyte?
Headquartered in Durham, North Carolina, Humacyte is a clinical-stage biotechnology company focused on the development and manufacture of bioengineered human tissues. The company's core innovation lies in its proprietary technology platform, which produces human acellular vessels (HAVs) that can be implanted into patients without triggering a foreign body response or immune rejection. This breakthrough technology addresses significant limitations in current synthetic and biological graft options, offering a transformative approach to vascular surgery and regenerative therapy.
Beyond vascular applications, Humacyte is exploring the delivery of cellular therapies, including pancreatic islet cell transplantation for the treatment of Type 1 diabetes. By leveraging its unique manufacturing capabilities, the company aims to redefine the standard of care across multiple therapeutic areas, positioning itself as a leader in the high-growth sector of regenerative medicine and advanced medical devices.
How much funding has Humacyte raised?
Humacyte has raised a total of $587.9M across 9 funding rounds:
Series B
$150M
Private Equity
$10M
Unspecified
$14.1M
Other Financing Round
$150M
Debt
$2M
Debt
$50M
Debt
$150M
Series B (2015): $150M supported by Access Industries, Bangkok Bank Public Company Ltd., and Reignwood Group
Private Equity (2016): $10M featuring California Institute for Regenerative Medicine
Unspecified (2017): $14.1M backed by California Institute of Regenerative Medicine
Other Financing Round (2018): $150M with participation from Fresenius Medical Care
Debt (2020): $2M led by PPP
Debt (2021): $50M supported by Silicon Valley Bank
Debt (2023): $150M featuring Oberland Capital
Key Investors in Humacyte
Access Industries
Access Industries is a privately-held industrial conglomerate founded in 1986 that makes strategic investments globally, maintaining a diversified portfolio that includes significant interests in the biotechnology sector.
Bangkok Bank Public Company Ltd.
Bangkok Bank is a major financial institution offering comprehensive domestic and international banking services, including specialized investment banking solutions.
Reignwood Group
Reignwood Group is a global enterprise with a strategic international platform that invests in a wide spectrum of industries, leveraging extensive financial resources to support innovation.
What's next for Humacyte?
Looking ahead, Humacyte is poised to leverage its recent capital injection to scale its manufacturing infrastructure and advance its late-stage clinical trials. The strategic focus remains on achieving regulatory milestones that will facilitate the commercial launch of its HAV portfolio. As the company moves deeper into the enterprise-level scaling phase, the integration of its technology into standard clinical practice will be the primary driver of long-term value creation. Investors and stakeholders are closely monitoring the company's progress in expanding its therapeutic reach, particularly in the high-demand markets of peripheral arterial disease and coronary artery bypass grafting, where the need for durable, non-immunogenic vascular solutions remains acute.
See full Humacyte company page
